Overview

Bioequivalence Study of Anastrozole 1 mg Tablet

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to characterize and compare the bioequivalence of CJ anastrozole [CJ Cheiljedang corp., Seoul, Korea] with Arimidex® [AstraZeneca, Wilmington, DE, USA].

Phase:

N/A

Details

Lead Sponsor:

Asan Medical Center

Collaborators:

CJ HealthCare Corporation
HK inno.N Corporation

Treatments:

Anastrozole